New tool offers personalized approach to blood cancer care

Researchers have developed a new tool to help clinicians tailor personalized treatment plans for patients with a rare blood ...
Nasdaq

Cardiff Presents Phase 1 Data Of Onvensertib In Chronic Myelomonocytic Leukemia At ASH 2025

(RTTNews) - Cardiff Oncology, Inc. (CRDF) has presented new clinical data from an investigator-sponsored Phase 1 dose escalation trial evaluating onvansertib, a novel oral PLK1 inhibitor, in patients ...
ascopubs.org

Hydroxyurea vs. hypomethylating vs. other agents in chronic myelomonocytic leukemia: A retrospective inspection of treatment strategies among 457 Mayo Clinic patients.

Maintenance therapy with azacitidine and valproic acid after allogeneic stem cell transplant in patients with high-risk myelodysplastic syndrome and acute myelogenous leukemia. QuANTUM-Wild: A phase 3 ...
Morningstar

OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting

NEW YORK, Dec. 1, 2025 /PRNewswire/ -- OncoPrecision Corporation ("OncoPrecision"), a translational therapeutics company developing novel antibody-based cancer therapies informed by large-scale ...
Stratford Herald

Family of Stratford milkman Len Watton raise £800 in his memory through charity walk around old milk round - with money going towards Blood Cancer UK

The family of a milkman who served Stratford for 45 years have raised almost £800 for charity through a walk along his old ...